Education
About Us
Working with TipRanks
Follow Us
Lexston Life Sciences Corp. (TSE:LEXT)
:LEXT
LEXT Stock Chart & Stats
C$0.10
<C$0.01(11.11%)
At close: 4:00 PM EST
C$0.10
<C$0.01(11.11%)
Day’s Range― - ―
52-Week RangeC$0.09 - C$0.58
Previous CloseN/A
Volume1.00M
Average Volume (3M)40.70K
Market Cap
C$2.13M
Enterprise ValueC$608.36K
Total Cash (Recent Filing)C$17.46K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta-0.25
Next Earnings
Apr 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding25,093,304
10 Day Avg. Volume77,591
30 Day Avg. Volume40,703
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)13.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
No Reported DebtNo reported debt lowers fixed obligations and reduces bankruptcy risk, giving management flexibility to prioritize R&D, commercialization, or strategic actions without immediate debt servicing pressure. Over a 2-6 month horizon this structural lack of leverage preserves optionality and improves capacity to negotiate financing or partnerships on less onerous terms.
Multi-year Reduction In Annual LossesA multi-year reduction in reported annual losses suggests the company has made operational adjustments or cost discipline that improved results through 2024. If sustained, this trend materially lowers the scale and frequency of external financings required, improves runway planning, and increases the likelihood of reaching breakeven on a medium-term timeline.
Spending Aligned With Reported LossesCash outflows that track reported operating losses indicate management is matching spending to operational scale instead of uncontrolled burn. This discipline enhances predictability of runway, supports prioritization of scarce cash toward value-driving projects, and reduces the risk of surprise liquidity shocks over the coming quarters.
Bears Say
No Meaningful RevenueEffectively zero revenue removes visibility into product-market fit, pricing power, and scalable unit economics. Without material sales the company cannot demonstrate sustainable margins or customer demand, forcing reliance on external capital and making forecasting and strategic scaling highly uncertain over a 2–6 month planning horizon.
Persistent Cash BurnSustained negative operating and free cash flow of roughly -$0.95M TTM indicates the business cannot self-fund operations or growth. Continued cash burn necessitates frequent external financing, raises dilution and refinancing risk, and constrains the company's ability to invest in commercialization, product development, or distribution in the medium term.
Ongoing Losses And Negative ROEA TTM net loss near -$1.45M and negative ROE (~-3.88%) show continued value erosion and poor capital efficiency. Persistent unprofitability diminishes the equity cushion, weakens investor confidence, and makes it harder to secure long-term financing or strategic partners until the company can produce consistent revenue or materially improve margins.
Lexston Life Sciences Corp. News
LEXT FAQ
What was Lexston Life Sciences Corp.’s price range in the past 12 months?
Lexston Life Sciences Corp. lowest stock price was C$0.09 and its highest was C$0.58 in the past 12 months.
What is Lexston Life Sciences Corp.’s market cap?
Lexston Life Sciences Corp.’s market cap is C$2.13M.
When is Lexston Life Sciences Corp.’s upcoming earnings report date?
Lexston Life Sciences Corp.’s upcoming earnings report date is Apr 03, 2026 which is in 45 days.
How were Lexston Life Sciences Corp.’s earnings last quarter?
Lexston Life Sciences Corp. released its earnings results on Jan 14, 2026. The company reported -C$0.022 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.022.
Is Lexston Life Sciences Corp. overvalued?
According to Wall Street analysts Lexston Life Sciences Corp.’s price is currently Overvalued.
Does Lexston Life Sciences Corp. pay dividends?
Lexston Life Sciences Corp. does not currently pay dividends.
What is Lexston Life Sciences Corp.’s EPS estimate?
Lexston Life Sciences Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lexston Life Sciences Corp. have?
Lexston Life Sciences Corp. has 25,093,304 shares outstanding.
What happened to Lexston Life Sciences Corp.’s price movement after its last earnings report?
Lexston Life Sciences Corp. reported an EPS of -C$0.022 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.263%.
Which hedge fund is a major shareholder of Lexston Life Sciences Corp.?
Currently, no hedge funds are holding shares in TSE:LEXT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lexston Life Sciences Corp.
Lexston Life Sciences Corp. operates as a biotechnology company that provides cannabis testing and research services in Canada. The company also offers analytical testing for cannabis, pathogens, and toxins. In addition, it focuses on developing and validating methods for standardized manufacturing of plant derived psychedelics in the field of mental health and wellness. The company is based in Vancouver, Canada.
Technical Analysis
Options Prices
Currently, No data available
---